|
Activity Number:
|
22
- Statistical Learning in Cancer Medicine: From Early-Phase Trials to Preclinical Systems
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Sunday, August 7, 2022 : 2:00 PM to 3:50 PM
|
|
Sponsor:
|
International Chinese Statistical Association
|
|
Abstract #323534
|
|
|
Title:
|
Treatment Response Data for Patient-Derived Xenografts
|
|
Author(s):
|
Michael Lloyd and Soner Koc and Anuj Srivastava and Vivek Philip and Tim Stearns and Carol Bult and Yvonne Evrard and Jeffrey Moscow and Funda Meric-Bernstam and Dennis Dean and Jeffrey H. Chuang*
|
|
Companies:
|
The Jackson Laboratory and Seven Bridges Genomics and The Jackson Laboratory and The Jackson Laboratory and The Jackson Laboratory and The Jackson Laboratory and Leidos Biomedical Research, Frederick National Laboratory for Cancer Research and Investigational Drug Branch, National Cancer Institute and The University of Texas MD Anderson Cancer Center and Seven Bridges Genomics and The Jackson Laboratory for Genomic Medicine
|
|
Keywords:
|
xenografts;
cancer;
treatment response;
preclinical trial;
PDXNet;
portal
|
|
Abstract:
|
Patient-derived xenografts (PDXs) are a model system in which human tumors are implanted in mice. PDXs are a precursor to clinical trials, but their statistical evaluation has been limited by available treatment response data. The new PDXNet Portal https://portal.pdxnetwork.org/ provides access to the NCI-funded PDXNet resources for PDXs from 936 patients. Some PDXs have been generated by PDXNet Testing Centers (307 patients across 33 cancer types). Others are from the NCI Patient Derived Models Repository (629 patients across 85 types). I will discuss treatment response data from these models covering single agents or agent combinations covering thousands of mice and volume measurements. With a RECIST-like classification scheme, 81% of treatment-model combinations were PD, 10% were SD, 5% were PR, and 4% were CR. I will describe the robustness of statistical metrics including tumor growth inhibition, area-under-the-curve, and others newly designed to aid advancement of clinical trials. Volume and linked sequence information from the portal will provide a key resource for advancing PDX treatment response analysis.
|
Authors who are presenting talks have a * after their name.
